series b

Insurance companies have been developing their social media networks. Tencent has upped the game by throwing its weight behind an insurance advisory service platform on WeChat.

Following a year of mega IPO flops, Chinese VC investment plummeted in the second quarter as private investors baulked at spiralling valuations. Staying private for longer will no longer be so easy for entrepreneurs.

Sino-US trade tensions have not discouraged Korean investors from China's booming biotech industry as the cancer immunology specialist completes its Series B funding.

Biofourmis, which uses bio-sensor technology and personalised predictive analytics, is moving to Boston after raising another $35 million. Next stop IPO.